Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Using machine learning, researchers find patterns in electronic health record data to better identify those likely to have the condition.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
The United States might see one of the steepest increases in the country’s uninsured rate in years.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
The CDC’s move triggered mixed feelings from the public and laid bare a split within the health care community.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
NIH-supported research will track effects of coronavirus infection on children over three years.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
MIS-C is a rare but life-threatening complication in which a hyperactive immune system attacks a child’s body.
Collins has led the NIH under three presidents over more than 12 years.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.